小剂量替罗非班联合双抗血小板治疗进展性脑梗死的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical effect of low dose Tirofiban combined with dual antiplatelet therapy in the treatment of progressive cerebral infarction. Methods A total of 46 patients with progressive cerebral infarction admitted to our hospital from January to December in 2018 were selected as the research objects, and they were divided into the control group (23 cases) and the observation group (23 cases) according to the random digital table method.The control group was treated with dual antiplatelet program, and the observation group was treated with low-dose Tirofiban combined with dual antiplatelet program.The scores of national institutes of health stroke scale (NIHSS),Barthel index, hypersensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), modified Rankin scale (mRS) and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P＜0.05).The NIHSS score of the observation group at 7 days after treatment was lower than that of the control group, the difference was statistically significant (P＜0.05).The Barthel index of the observation group at 7 days after treatment was higher than that of the control group, the difference was statistically significant (P＜0.05).The levels of hs-CRP and IL-6 in the observation group at 14 days after treatment were lower than those in the control group, the difference was statistically significant (P＜0.05).The mRS score of the observation group after treatment was lower than that of the control group, and the difference was statistically significant (P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Low dose Tirofiban combined with dual antiplatelet regimen can achieve good therapeutic effect in the treatment of progressive cerebral infarction.

Key words： Low dose Tirofiban Dual antiplatelet therapy Progressive cerebral infarction Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Gan
	WU Wei-Juan
	YAN Zi-le
	LI Gui-lan
	CHEN Yi-min

Cite this article:

CHEN Gan,WU Wei-Juan,YAN Zi-le, et al. Clinical effect of low-dose Tirofiban combined with dual antiplatelet therapy in the treatment of progressive cerebral infarction[J]. 中国当代医药, 2020, 27(15): 83-85转89.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I15/83

[1]	刘梦婵，李凤鹏，韩雅玲，等.阿加曲班对比阿司匹林联合氯吡格雷治疗急性缺血性卒中的初步随机、开放研究[J].解放军医学杂志，2015，40（6）：433-439.
[2]	宋彦，丁旭萌，李旭，等.超声监测老年进展性脑梗死与颈动脉斑块稳定性的关系及进展性脑梗死的危险因素[J].中国老年学杂志，2018，38（23）：5670-5673.
[3]	刘小军，吴开毅，刘南午，等.巴曲酶注射液联合丁苯酞注射液治疗急性进展性脑梗死的临床研究[J].中国临床药理学杂志，2018，34（15）：1751-1754.
[4]	杨科敏，王卓彪，杨梅，等.丁苯酞联合丹参多酚酸治疗进展性脑梗死临床观察[J].中国药物与临床，2019，19（1）：81-83.
[5]	Birschel P，Ellul J，Barer D，et al.Progressing stroke：towaids an internationlly agreed definition[J].Cerebrovase Dis，2004，17（2/3）：242-252.
[6]	刘深龙，辛立建，马媛媛，等.替罗非班在进展性脑梗死治疗中的应用效果及对患者血清炎性因子、血小板功能的影响[J].山东医药，2019，59（17）：44-46.
[7]	王升，刘梦，郑远征，等.小剂量替罗非班与双抗治疗进展性脑卒中的疗效对比及安全性评价[J].中国实用神经疾病杂志，2017，20（8）：23-25.
[8]	郝静，赵娜，孔孟丹，等.替罗非班治疗进展性缺血性卒中的疗效和安全性观察[J].解放军医学院学报，2017，38（5）：409-413.
[9]	孙琦.进展性脑梗死影响因素分析[J].中国医药导报，2015，12（4）：56-59.
[10]	徐耀铭，齐晓飞，王姝瑶，等.急性脑梗死早期进展相关危险因素的临床研究[J].中风与神经疾病杂志，2018，35（6）：548-549.
[11]	张玉蛟，刘新胜，白冰，等.进展性脑梗死预测因素与预后分析[J].中国实用神经疾病杂志，2018，21（5）：535-538.
[12]	贾小影，李淞，李丽，等.应用TCD 评价经典双抗治疗对急性脑梗死患者脑血管储备功能的影响[J].中国老年学杂志，2017，37（21）：5287-5288.
[13]	李兰红，王晋芳.阿司匹林联合氯吡格雷治疗急性进展性脑梗死的疗效观察[J].中西医结合心脑血管病杂志，2016，14（16）：1926-1927.
[14]	李坷，张继中，张钦昌.国产替罗非班在急性进展性脑梗死治疗中的应用[J].中国实用神经疾病杂志，2017，20（1）：117-118.
[15]	邱涛，戴晓艳，黄琳明，等.小牛血清去蛋白联合替罗非班治疗进展性脑梗死的疗效观察[J].现代药物与临床，2016，31（7）：965-968.